Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. [electronic resource]
Producer: 20131107Description: 1982-93 p. digitalISSN:- 1097-0215
- Animals
- Antineoplastic Agents, Alkylating -- pharmacology
- Apoptosis -- drug effects
- Caspase 3 -- metabolism
- Caspase 7 -- metabolism
- Caspase 9 -- metabolism
- Cathepsin B -- biosynthesis
- Cell Cycle Checkpoints -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cytochromes c -- metabolism
- DNA Damage
- Dacarbazine -- analogs & derivatives
- Drug Synergism
- Female
- Folic Acid Antagonists -- pharmacology
- Histones -- metabolism
- Leucovorin -- pharmacology
- Matrix Metalloproteinase 2 -- biosynthesis
- Matrix Metalloproteinase 9 -- biosynthesis
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Mitochondria -- drug effects
- Neoplasm Invasiveness
- Neoplasm Transplantation
- Phosphorylation -- drug effects
- Pituitary Neoplasms -- drug therapy
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerases -- metabolism
- Proto-Oncogene Proteins c-bcl-2 -- biosynthesis
- Pyrimethamine -- pharmacology
- Rats
- Temozolomide
- Up-Regulation -- drug effects
- Xenograft Model Antitumor Assays
- bcl-2-Associated X Protein -- biosynthesis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.